- Pyrazinyl-substituted naphthalene derivatives
-
Compounds of the formula where R1 is of the formulae R2 is —R4, —O—R4, —O—S (O)2—R4, —NR4R5, R4—(CH2)b—NH(C═X)—(CH2)—, R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—, R4(C═O)NH—(C═O)NH—, —(CH2)b—NH(C═X)—(CH2)c—R4, R4—(CH2)b—O(C═)—(CH2)c—, —(CH2)b—O(C═O)—(CH2)c—R4, —NH(C═X)NH—R4, R4—O(C═O)O—, —O(C═)NH—R4, R4—O(C═O)NH—, —(CH2)b—(C═0)—(CH2)c—R4, —NH—S(O)2—R4, —C(OH)R4R5, —CH(OH)—R4, —(C═O)—NR4R5, —CN, —NO2, substituted C1 to C6 alkyl, substituted or unsubstituted C1 to C6 alkenyl, or substituted or unsubstituted C1 to C6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R4, —R4R5, —O—R4, or —S(O)d—R4. These compounds are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.
- -
-
-